Clark Pharma Limited - Period Ending 2019-06-30

Clark Pharma Limited - Period Ending 2019-06-30


Clark Pharma Limited 10710051 false 2018-07-01 2019-06-30 2019-06-30 The principal activity of the company is the management of a pharmacy. Digita Accounts Production Advanced 6.24.8820.0 Software false 10710051 2018-07-01 2019-06-30 10710051 2019-06-30 10710051 core:RetainedEarningsAccumulatedLosses 2019-06-30 10710051 core:ShareCapital 2019-06-30 10710051 core:CurrentFinancialInstruments 2019-06-30 10710051 core:CurrentFinancialInstruments core:WithinOneYear 2019-06-30 10710051 core:Non-currentFinancialInstruments core:AfterOneYear 2019-06-30 10710051 core:MoreThanFiveYears 1 2019-06-30 10710051 core:MoreThanFiveYears 2 2019-06-30 10710051 core:OfficeEquipment 2019-06-30 10710051 bus:SmallEntities 2018-07-01 2019-06-30 10710051 bus:AuditExemptWithAccountantsReport 2018-07-01 2019-06-30 10710051 bus:FullAccounts 2018-07-01 2019-06-30 10710051 bus:SmallCompaniesRegimeForAccounts 2018-07-01 2019-06-30 10710051 bus:RegisteredOffice 2018-07-01 2019-06-30 10710051 bus:Director1 2018-07-01 2019-06-30 10710051 bus:Director4 2018-07-01 2019-06-30 10710051 bus:PrivateLimitedCompanyLtd 2018-07-01 2019-06-30 10710051 core:OfficeEquipment 2018-07-01 2019-06-30 10710051 core:AllSubsidiaries 2018-07-01 2019-06-30 10710051 countries:AllCountries 2018-07-01 2019-06-30 10710051 core:CostValuation 2018-06-30 10710051 core:OfficeEquipment 2018-06-30 10710051 2018-06-30 10710051 core:RetainedEarningsAccumulatedLosses 2018-06-30 10710051 core:ShareCapital 2018-06-30 10710051 core:CurrentFinancialInstruments 2018-06-30 10710051 core:CurrentFinancialInstruments core:WithinOneYear 2018-06-30 10710051 core:Non-currentFinancialInstruments core:AfterOneYear 2018-06-30 10710051 core:MoreThanFiveYears 1 2018-06-30 10710051 core:MoreThanFiveYears 2 2018-06-30 10710051 core:OfficeEquipment 2018-06-30 iso4217:GBP

Registration number: 10710051

Clark Pharma Limited

Filleted Annual Report and Unaudited Financial Statements

for the Year Ended 30 June 2019

 

Clark Pharma Limited

Contents

Statement of Financial Position

1 to 2

Notes to the Unaudited Financial Statements

3 to 8

 

Clark Pharma Limited

(Registration number: 10710051)
Statement of Financial Position as at 30 June 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

3

193

285

Investment property

4

207,149

-

Investments

5

2,685,448

2,685,448

 

2,892,790

2,685,733

Current assets

 

Debtors

6

4,890

480

Cash at bank and in hand

 

1,078

632

 

5,968

1,112

Creditors: Amounts falling due within one year

7

(268,001)

(270,456)

Net current liabilities

 

(262,033)

(269,344)

Total assets less current liabilities

 

2,630,757

2,416,389

Creditors: Amounts falling due after more than one year

7

(2,422,255)

(2,337,058)

Provisions for liabilities

(33)

(54)

Net assets

 

208,469

79,277

Capital and reserves

 

Called up share capital

200

200

Profit and loss account

208,269

79,077

Total equity

 

208,469

79,277

For the financial year ending 30 June 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies' regime and the option not to file the Income Statement has been taken.

Approved and authorised by the Board on 19 March 2020 and signed on its behalf by:
 

 

Clark Pharma Limited

(Registration number: 10710051)
Statement of Financial Position as at 30 June 2019 (continued)

.........................................
Mr G Clark
Director

.........................................
Mr K A Simpson
Director

 
     
 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is 18 Ambleside Court, Chester le Street, County Durham, DH3 2EB.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are prepared in sterling which is the functional currency of the entity.

Group accounts not prepared

In the opinion of the directors, the company and its subsidiary undertaking comprise a small group. The company has therefore taken advantage of the exemption provided by Section 398 of the Companies Act 2006 not to prepare group accounts.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019 (continued)

2

Accounting policies (continued)

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Asset class

Depreciation method and rate

 

Office equipment

25% straight line

Investment property

Investment property is carried at fair value, derived from the current market prices for comparable real estate determined annually by external valuers. The valuers use observable market prices, adjusted if necessary for any difference in the nature, location or condition of the specific asset. Changes in fair value are recognised in profit or loss.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment. Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019 (continued)

2

Accounting policies (continued)

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Income Statement over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019 (continued)

3

Tangible assets

Office equipment
£

Cost or valuation

Additions

370

At 30 June 2019

370

Depreciation

At 1 July 2018

85

Charge for the year

92

At 30 June 2019

177

Carrying amount

At 30 June 2019

193

At 30 June 2018

285

4

Investment properties

2019
£

Additions

207,149

At 30 June

207,149

There has been no valuation of investment property by an independent valuer.

5

Investments

2019
£

2018
£

Investments in subsidiaries

2,685,448

2,685,448

Subsidiaries

£

Cost or valuation

At 1 July 2018

2,685,448

Provision

Carrying amount

At 30 June 2019

2,685,448

At 30 June 2018

2,685,448

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019 (continued)

6

Debtors

2019
£

2018
£

Amounts owed by group undertakings

-

480

Prepayments

640

-

Other debtors

4,250

-

4,890

480

7

Creditors

Creditors: amounts falling due within one year

2019
£

2018
£

Due within one year

Bank loans

116,725

107,992

Taxation and social security

7,167

7,333

Accruals and deferred income

1,250

1,250

Other creditors

-

480

Corporation tax liability

18,059

28,601

Directors loan accounts

124,800

124,800

268,001

270,456

Creditors include bank loans repayable by instalments of £116,725 (2018: £107,992). Bank borrowings are secured against the assets of the company.

Creditors: amounts falling due after more than one year

2019
£

2018
£

Due after one year

Bank loans

1,097,255

1,012,058

Other non-current financial liabilities

1,325,000

1,325,000

2,422,255

2,337,058

2019
£

2018
£

Due after more than five years

After more than five years by instalments

591,751

543,862

After more than five years not by instalments

1,325,000

1,325,000

1,916,751

1,868,862

-

-

Creditors include bank loans repayable by instalments of £1,097,255 (2018: £1,012,058). Borrowings are secured against the assets of the company.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2019 (continued)

7

Creditors (continued)

Creditors falling due after more than one year includes £1,325,000 convertible loan notes bearing interest at a rate of 1.75% above the Bank of England Base Rate. The maturity date is July 2027.

Creditors include bank loans repayable by instalments of £591,751 (2018: £543,862) due after more than five years.

8

Related party transactions

Summary of transactions with all subsidiaries

During the period, the company made management charges totalling £160,417 (2018: £215,000) to a subsidiary undertaking.